Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
2011

Genetic Variants and Alzheimer's Disease Biomarkers

Sample size: 664 publication Evidence: low

Author Information

Author(s): Kauwe John S. K., Cruchaga Carlos, Karch Celeste M., Sadler Brooke, Lee Mo, Mayo Kevin, Latu Wayne, Su'a Manti, Fagan Anne M., Holtzman David M., Morris John C., Goate Alison M.

Primary Institution: Washington University School of Medicine

Hypothesis

Are variants in BIN1, CLU, CR1, and PICALM associated with cerebrospinal fluid biomarkers for Alzheimer's disease?

Conclusion

The study found no significant association between the genetic variants and cerebrospinal fluid levels of Aβ42 or ptau181.

Supporting Evidence

  • 355 genetic variants were analyzed in over 600 individuals.
  • No significant associations were found between the SNPs and CSF biomarker levels.
  • The study had adequate power to detect effects as small as a 1.05 fold difference.
  • Previous studies suggested additive effects of CLU and APOE on Aβ deposition.
  • Findings suggest that genetic variants may not directly alter CSF levels of Aβ42 or ptau181.

Takeaway

The researchers looked for links between certain genes and Alzheimer's disease markers in the brain but didn't find any strong connections.

Methodology

The study involved genotyping 355 variants in over 600 individuals and analyzing their cerebrospinal fluid biomarker levels.

Limitations

The study may not detect rare variations or complex interactions that could influence biomarker levels.

Participant Demographics

The sample included 407 individuals from Washington University and 257 from the Alzheimer's Disease Neuroimaging Initiative, with a mix of cases and controls.

Statistical Information

P-Value

p=0.31, p=0.44, p=0.48

Digital Object Identifier (DOI)

10.1371/journal.pone.0015918

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication